Search Results

There are 22700 results for: content related to: Exposure to opioid maintenance treatment reduces long-term mortality

  1. Buprenorphine for managing opioid withdrawal

    Intervention Review

    The Cochrane Library

    Linda Gowing, Robert Ali, Jason M White and Dalitso Mbewe

    Published Online : 21 FEB 2017, DOI: 10.1002/14651858.CD002025.pub5

  2. You have free access to this content
    Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

    Intervention Review

    The Cochrane Library

    Richard P Mattick, Courtney Breen, Jo Kimber and Marina Davoli

    Published Online : 6 FEB 2014, DOI: 10.1002/14651858.CD002207.pub4

  3. You have free access to this content
    Buprenorphine for treating cancer pain

    Intervention Review

    The Cochrane Library

    Mia Schmidt-Hansen, Nathan Bromham, Mark Taubert, Stephanie Arnold and Jennifer S Hilgart

    Published Online : 31 MAR 2015, DOI: 10.1002/14651858.CD009596.pub4

  4. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers

    Addiction

    Volume 105, Issue 4, April 2010, Pages: 709–718, Sandra D. Comer, Maria A. Sullivan, Suzanne K. Vosburg, Jeanne Manubay, Leslie Amass, Ziva D. Cooper, Phillip Saccone and Herbert D. Kleber

    Version of Record online : 10 MAR 2010, DOI: 10.1111/j.1360-0443.2009.02843.x

    Corrected by:

    Erratum

    Vol. 105, Issue 7, 1322, Version of Record online: 8 JUN 2010

  5. Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials

    The Journal of Clinical Pharmacology

    Volume 46, Issue 2, February 2006, Pages: 179–192, Dr Domenic A. Ciraulo, Dr Robert J. Hitzemann, Dr Eugene Somoza, Dr Clifford M. Knapp, Dr John Rotrosen, Dr Ofra Sarid-Segal, Ms Ann Marie Ciraulo, Dr David J. Greenblatt and Dr C. Nora Chiang

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270005284192

  6. The clinical use of buprenorphine in opiate addiction: evidence and practice

    Acta Neuropsychiatrica

    Volume 16, Issue 5, October 2004, Pages: 246–274, Fergus D. Law, Judy S. Myles, Mark R. C. Daglish and David J. Nutt

    Version of Record online : 11 FEB 2005, DOI: 10.1111/j.0924-2708.2004.00095.x

  7. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties

    The Milbank Quarterly

    Volume 93, Issue 3, September 2015, Pages: 561–583, BRADLEY D. STEIN, ROSALIE LICCARDO PACULA, ADAM J. GORDON, RACHEL M. BURNS, DOUGLAS L. LESLIE, MARK J. SORBERO, SEBASTIAN BAUHOFF, TODD W. MANDELL and ANDREW W. DICK

    Version of Record online : 8 SEP 2015, DOI: 10.1111/1468-0009.12137

  8. You have free access to this content
    Post-marketing Surveillance of Methadone and Buprenorphine in the United States

    Pain Medicine

    Volume 11, Issue 7, July 2010, Pages: 1078–1091, Nabarun Dasgupta, Elise J. Bailey, Theodore Cicero, James Inciardi, Mark Parrino, Andrew Rosenblum and Richard C. Dart

    Version of Record online : 8 JUN 2010, DOI: 10.1111/j.1526-4637.2010.00877.x

  9. Buprenorphine in Maintenance Treatment: Experience among Italian Physicians in Drug Addiction Centers

    The American Journal on Addictions

    Volume 19, Issue 3, May-June 2010, Pages: 222–230, Gianluca Quaglio, Cristian Pattaro, Gilberto Gerra, Paolo Mezzelani, Linda Montanari, Don C. Des Jarlais and Fabio Lugoboni

    Version of Record online : 2 APR 2010, DOI: 10.1111/j.1521-0391.2010.00040.x

  10. Bringing Buprenorphine-Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience

    The American Journal on Addictions

    Volume 13, Issue S1, May-June 2004, Pages: S42–S66, Leslie Amass, Walter Ling, Thomas E. Freese, Chris Reiber, Jeffrey J. Annon, Allan J. Cohen, Dennis McCarty, Malcolm S. Reid, Lawrence S. Brown Jr., Cynthia Clark, Douglas M. Ziedonis, Jonathan Krejci, Susan Stine, Theresa Winhusen, Greg Brigham, Dean Babcock, Joan A. Muir, Betty J. Buchan and Terry Horton

    Version of Record online : 18 FEB 2010, DOI: 10.1080/10550490490440807

  11. You have free access to this content
    Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review

    Addiction

    Volume 107, Issue S1, November 2012, Pages: 5–27, Hendrée E. Jones, Sarah H. Heil, Andjela Baewert, Amelia M. Arria, Karol Kaltenbach, Peter R. Martin, Mara G. Coyle, Peter Selby, Susan M. Stine and Gabriele Fischer

    Version of Record online : 29 OCT 2012, DOI: 10.1111/j.1360-0443.2012.04035.x

  12. Buprenorphine-Based Regimens and Methadone for the Medical Management of Opioid Dependence: Selecting the Appropriate Drug for Treatment

    The American Journal on Addictions

    Volume 19, Issue 6, November-December 2010, Pages: 557–568, Icro Maremmani and Gilberto Gerra

    Version of Record online : 21 SEP 2010, DOI: 10.1111/j.1521-0391.2010.00086.x

  13. Comparison of costs and utilization among buprenorphine and methadone patients

    Addiction

    Volume 104, Issue 6, June 2009, Pages: 982–992, Paul G. Barnett

    Version of Record online : 6 MAY 2009, DOI: 10.1111/j.1360-0443.2009.02539.x

  14. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine

    European Journal of Pain

    Volume 13, Issue 3, March 2009, Pages: 219–230, Hans G. Kress

    Version of Record online : 9 JAN 2012, DOI: 10.1016/j.ejpain.2008.04.011

  15. Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile

    Pain Practice

    Volume 10, Issue 5, September/October 2010, Pages: 428–450, Joseph Pergolizzi, Anna Maria Aloisi, Albert Dahan, Joerg Filitz, Richard Langford, Rudolf Likar, Sebastiano Mercadante, Bart Morlion, Robert B. Raffa, Rainer Sabatowski, Paola Sacerdote, Luis M. Torres and Avi A. Weinbroum

    Version of Record online : 17 MAY 2010, DOI: 10.1111/j.1533-2500.2010.00378.x

  16. You have free access to this content
    The effectiveness of a long-acting transdermal fentanyl solution compared to buprenorphine for the control of postoperative pain in dogs in a randomized, multicentered clinical study

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 35, Issue s2, August 2012, Pages: 53–64, D. D. LINTON, M. G. WILSON, G. C. NEWBOUND, K. J. FREISE and T. P. CLARK

    Version of Record online : 25 JUN 2012, DOI: 10.1111/j.1365-2885.2012.01408.x

  17. FROM WHITE BULLETS TO BLACK MARKETS AND GREENED MEDICINE: THE NEUROECONOMICS AND NEURORACIAL POLITICS OF OPIOID PHARMACEUTICALS

    Annals of Anthropological Practice

    Volume 36, Issue 1, May 2012, Pages: 167–182, Helena Hansen and Mary E. Skinner

    Version of Record online : 19 SEP 2012, DOI: 10.1111/j.2153-9588.2012.01098.x

  18. The Impact of Prior Authorization on Buprenorphine Dose, Relapse Rates, and Cost for Massachusetts Medicaid Beneficiaries with Opioid Dependence

    Health Services Research

    Volume 49, Issue 6, December 2014, Pages: 1964–1979, Robin E. Clark, Jeffrey D. Baxter, Bruce A. Barton, Gideon Aweh, Elizabeth O'Connell and William H. Fisher

    Version of Record online : 9 JUL 2014, DOI: 10.1111/1475-6773.12201

  19. Arrhythmia associated with buprenorphine and methadone reported to the food and drug administration

    Addiction

    Volume 110, Issue 9, September 2015, Pages: 1468–1475, David P. Kao, Mark C. P. Haigney, Philip S. Mehler and Mori J. Krantz

    Version of Record online : 29 JUL 2015, DOI: 10.1111/add.13013

  20. The history of the development of buprenorphine as an addiction therapeutic

    Annals of the New York Academy of Sciences

    Volume 1248, Issue 1, February 2012, Pages: 124–139, Nancy D. Campbell and Anne M. Lovell

    Version of Record online : 18 JAN 2012, DOI: 10.1111/j.1749-6632.2011.06352.x